The Brand Was Recently Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2024 and a NEXTY Award Winner

iTOL-100 technology has broad applicability and can be applied to both allogenic and stem cell-derived organoids across a number of diseases.

Manufacturing agreement supports advancement of iTolerance's development of iTOL-100 towards first in human clinical study for lead program, iTOL-102.

Agbotic's climate-smart farm technology grows crops at a lower cost of production than hydroponic greenhouses and vertical farms and is approaching economic parity with outdoor farming.

Leading Farm, Food, and Retail Corporations Investing in Carbon Drawdown

Leading U.S-based stem cell research and treatment company begins clinical trial — similar to one just approved by the FDA and first such study ever approved by Colombian government healthcare regulator.

The Phase 2 study will assess the safety and efficacy of Longeveron's stem cell treatment under Japan's accelerated regulatory pathway for regenerative medicine.

Center Provides Scientific Education and Training for Regenerative Medicine

Report shows double bottom line return of 7.3 percent annual ecosystem gain on top of 10.5 percent annualized net economic gain for investors

Maxx-Cell has created a new gold standard in bone marrow aspiration therapy.

Harvard Bioscience's regenerative medicine devices are used by surgeons and scientists to grow tissues and organs for transplant